To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80
mg) manufactured at the Totowa, NJ facility relative to the formulation (80 mg) manufactured
at the Wilson, NC facility in the fasted state.